Multiple myeloma is a plasma cell cancer affecting bone marrow, causing bone issues. Myelofibrosis is a disorder of blood cell production, leading to scarring of the bone marrow. They differ in origin, symptoms and treatments.

Multiple myeloma is a cancer of plasma cells, leading to bone-related symptoms, while myelodysplastic syndromes involve dysfunctional blood cell production. Distinct in origin, symptoms and treatments, both require individualized care.

In contrast to leukemia, a cancer characterized by immature blood cells circulating in the bloodstream, myeloma cells typically remain localized in the bone marrow. The challenges posed by myeloma cells and the treatment approaches differ from those of leukemia.

Refractory multiple myeloma is a form of blood cancer that fails to improve or ceases to respond to treatment.

In multiple myeloma, a paraprotein level refers to the abnormal monoclonal protein produced by cancerous plasma cells. This elevated level can be detected through tests like serum protein electrophoresis and immunofixation, aiding in diagnosis and treatment planning.

Cutaneous itching in multiple myeloma can be caused by treatments or, rarely, by complications associated with the cancer.

While multiple myeloma and leukemia are both cancers of the blood and bone marrow, they arise from different types of cells. Multiple myeloma originates from plasma cells, while leukemia starts in the early forms of white blood cells. It’s rare for myeloma to “turn into” leukemia. However, some treatments for multiple myeloma, especially certain chemotherapies, […]

Yes, kidney failure is a possible complication of multiple myeloma. The cancerous cells produce abnormal proteins which can deposit in the kidneys, impairing their function. Additionally, elevated calcium levels due to bone breakdown can further stress the kidneys. Early detection and intervention, including hydration and specific treatments, can help prevent or manage kidney complications.